IBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

iBio Inc. stock falls Wednesday, underperforms market

"The weekly claims was big news this morning, good news being construed as bad news and it's hard to ignore the news out of China" about Apple said Sahak Manuelian, managing director and head of equity trading at Wedbush Securities. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Top institutional investors include Avantax Planning Partners Inc. (0.92%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Martin Brenner and Robert Matthew Lutz. Shristi is a correspondent, part of the markets team reporting on the stock markets across U.S., UK, Canada, Europe and Emerging markets. On U.S. exchanges 9.76 billion shares changed hands compared with the 10.10 billion moving average for the last 20 sessions. The Philadelphia semiconductor index (.SOX) fell 1.98% while shares of Apple suppliers including Skyworks Solutions (SWKS.O), Qualcomm (QCOM.O) and Qorvo (QRVO.O) all fell more than 7%.

Coronavirus update: At least 425 deaths, 176 confirmed cases outside of China, S&P predicts outbreak will stabilize in April

A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBIO, but not buy additional shares or sell existing shares. Shares of iBio Inc. rocketed 64% on heavy volume in premarket trading Friday, as the biotherapeutics and contract manufacturing company is set to be added to the Russell and Russell indexes. Also denting sentiment about the world's second-largest economy, data showed China's exports and imports fell in August. Rick Meckler, partner at Cherry Lane Investments said the news from China refocused investors on the idea "that the relationship between the U.S. and China is a big risk to current equity prices, particularly in technology." Minutes before the close, New York Fed President John Williams said it was an "open question" whether monetary policy is restrictive enough to bring the economy back into balance.

• Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.
• Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
• The Philadelphia semiconductor index (.SOX) fell 1.98% while shares of Apple suppliers including Skyworks Solutions (SWKS.O), Qualcomm (QCOM.O) and Qorvo (QRVO.O) all fell more than 7%.
• IBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States.
• Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed.

Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer. Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below https://bigbostrade.com/ and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can. Shares of tiny biotech iBio Inc. surged another 19% in premarket trade Thursday, on continued strong hopes for its partnership with a Chinese company on a plant-based vaccine to treat the coronavirus.

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

The company is scheduled to release its next quarterly earnings announcement on Monday, September 25th 2023. Also helping to keep the Dow afloat was a 1% rise in McDonald's (MCD.N) shares after Wells Fargo upgraded the stock to "overweight". etf trading strategies The Dow outperformed the S&P and Nasdaq because Apple has a lower weighting in the cyclicals-heavy index, which is price-weighted compared with the market capitalization-weighted S&P 500 (.SPX.), where Apple is one of the biggest weights.

Shares of iBio Inc. soared another 174% Friday, bringing their weekly gain to 689%, on hopes for the company's partnership with Beijing CC-Pharming Ltd. on a plant-based vaccine to treat the coronavirus. Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates from . Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.

Ibio Inc Company Profile

According to 2 analysts, the average rating for IBIO stock is "Hold." The 12-month stock price forecast is $4.25, which is an increase of 1,228.13% from the latest price. As of August 15th, there was short interest totaling 279,600 shares, a decline of 40.7% from the July 31st total of 471,700 shares. Based on an average trading volume of 654,500 shares, the days-to-cover ratio is currently 0.4 days. 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. The consensus among Wall Street research analysts is that investors should "hold" IBIO shares.

IBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Analyst Ratings

"We’ve got policy in a good place, but we’re going to need to continue to be data dependent,” he said, pointing to upcoming data releases due before the Fed's September meeting. Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. U.S. stocks are facing a triple threat from a stronger U.S. dollar, rising Treasury yields and higher oil prices that could further erode gains accrued by the main indexes since the start of 2023, analysts told MarketWatch. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. IBio's stock is owned by a variety of institutional and retail investors.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year.

Rate hike concerns weigh on European shares ahead of US inflation test

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum.